SG Pharma Solutions
SG PHARMASOLUTIONS
SG Pharma Solutions
SG PHARMASOLUTIONS

Pillar 2: Medical Device Safety

Medical Device Safety & Chemical Characterization

End-to-end biological safety strategy, ISO 10993-18 chemical characterization, simulated-use study coordination, toxicological risk assessment, and ISO 14971 risk-management linkage.

Medical Device Safety Chemical Characterization and Analysis
Regulatory & Biological Safety

Chemical Characterization Aligned with ISO 10993 & ISO 14971

Demonstrating the biological safety of medical devices requires a structured, science-driven pathway. Modern global regulatory bodies (including US FDA, EU Notified Bodies, and PMDA) mandate that biological evaluation starts with a thorough understanding of device materials and chemical characterization before initiating unnecessary animal testing.

At SG Pharma Solutions, we provide high-level technical consultancy and coordination throughout the biological evaluation lifecycle. We establish the Biological Evaluation Plan (BEP), define extraction rationales per ISO 10993-18, coordinate physical analytical testing through qualified partner laboratories, conduct toxicological risk assessments per ISO 10993-17, and synthesize the findings into a defensible Biological Evaluation Report (BER) directly linked to your ISO 14971 risk management file.

Technical Distinction: SG Pharma Solutions provides technical strategy, protocol design, toxicological assessment, and documentation support. Physical chemical extraction and laboratory testing are executed through vetted, independent testing laboratories.

Relevant Device Applications

Implants

Long-term and permanent implantable devices requiring exhaustive chemical extraction and toxicological risk assessment.

Catheters & Vascular Access

Circulating blood-contacting devices with strict hemocompatibility and chemical leaching considerations.

Patient-Contacting Devices

Short-term, transient, and prolonged contact medical devices per ISO 10993-1 categorized endpoints.

Drug-Device Combination Products

Cross-boundary delivery devices combining pharmaceutical API compatibility with medical device mechanical safety.

Drug-Delivery Systems

Prefilled syringes, autoinjectors, pen injectors, and nebulizer components.

Medical Device Components & Materials

Raw polymers, elastomers, adhesives, surface coatings, colorants, and metallic alloys.

Scope of Support

Comprehensive Medical Device Safety Capabilities

From early material assessment through toxicological threshold calculation and submission dossier authoring.

01

Material Assessment & Gap Analysis

Comprehensive evaluation of constituent polymers, metals, ceramics, colorants, and processing aids to identify chemical risks and prior safety history.

02

ISO 10993-18 Chemical Characterization Strategy

Design of exaggerated, exhaustive, and simulated-use extraction studies, calculation of Analytical Evaluation Thresholds (AET), and analytical technique selection.

03

Simulated-Use & Leachables Coordination

Coordination of clinically relevant simulated-use studies mimicking real-world patient contact conditions in collaboration with partner laboratories.

04

Biological Safety & Endpoint Strategy

Strategic identification of required biological endpoints (cytotoxicity, sensitization, irritation, systemic toxicity, hemocompatibility) per ISO 10993-1.

05

Toxicological Assessment Coordination

Derivation of Tolerable Intake (TI) / Tolerable Exposure (TE) and Margin of Safety (MOS) per ISO 10993-17 for all quantitated extractable and leachable compounds.

06

ISO 14971 Risk-Management Linkage

Direct integration of chemical characterization and toxicological evaluation data into the medical device Risk Management File (RMF).

07

BEP & BER Dossier Authoring Support

Formulation of Biological Evaluation Plans (BEP) prior to testing and compilation of Biological Evaluation Reports (BER) for submission.

08

Regulatory Documentation & Submission Support

Authoring comprehensive technical documentation for FDA 510(k), PMA, De Novo, and EU MDR CE Mark technical documentation.

Structured Methodology

Integrated ISO 10993 Safety & Risk Architecture

A logical progression that connects material characterization directly to clinical patient safety.

Phase 1

BEP & Material Assessment

Evaluating device materials, manufacturing aids, prior clinical history, and drafting the Biological Evaluation Plan.

Phase 2

ISO 10993-18 Testing

Coordinating solvent extraction, AET calculation, and LC-MS / GC-MS / ICP-MS profiling with accredited laboratories.

Phase 3

Toxicological Evaluation

Reviewing chromatograms, deriving TI/TE and Margin of Safety (MOS) per ISO 10993-17.

Phase 4

BER & ISO 14971 Integration

Compiling the final Biological Evaluation Report and integrating residual risk mitigations into the Risk Management File.